Amgen Stock - Phase 3 obesity data and analyst focus
17.06.2026 - 21:06:40 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 19:05 UTC. Details in the imprint.
Amgen (US0311621009) is drawing renewed attention from investors as the company advances its obesity pipeline and prepares for the next stage of competition with established players in metabolic disease. According to recent management commentary and clinical updates, the biotech group is refining its Phase 3 strategy while markets reassess the long-term revenue potential of its weight-loss program.
Background and price data on Amgen stock
All current news, filings and historical data points on Amgen stock can be found in the dedicated topic area and via the company’s investor relations pages.
Obesity program shapes the narrative
Amgen’s obesity franchise has become a central pillar of the investment story, with the company positioning its experimental therapies as potential rivals to blockbuster drugs from Eli Lilly and Novo Nordisk. Management has repeatedly highlighted obesity and cardiometabolic disease as key long-term growth drivers in investor presentations.
In recent conference appearances, executives underlined that Amgen is working through late-stage trial design choices and regulatory discussions for its next-generation obesity candidates, framing the program as a multi-year revenue opportunity rather than a short tactical bet.
Midweek focus on operations and pipeline
At midweek, the market’s attention centers on Amgen’s operational execution, including how it allocates research and development resources between obesity, oncology and autoimmune diseases. The company has stressed disciplined capital deployment and a focus on programs that can move the revenue needle in the 2030s.
Analysts tracking the name often model substantial potential sales from obesity therapies in their long-range scenarios but also emphasize execution risk, given the need for large cardiovascular outcome studies, manufacturing scale-up and payor negotiations, which can all influence eventual margins.
The product behind the stock
Amgen generates revenue primarily from biologic therapies for serious illnesses, including oncology, inflammation and bone health, and is developing new cardiometabolic and obesity treatments. Its portfolio combines established blockbusters with a pipeline of antibody-based and other advanced medicines targeting high-unmet-need indications.
Where the stock trades today
The shares of Amgen trade on Nasdaq at USD 300.00 as of 06/17/2026, 19:05 UTC.
Key facts on Amgen stock
- Company: Amgen Inc.
- ISIN: US0311621009
- WKN: 867900
- Ticker: AMGN
- Venue: Nasdaq
- Price (as of 06/17/2026, 19:05 UTC): 300.00 USD
- Market cap: 160,000,000,000 USD (as of 06/17/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
